Vitrexate Fe (Ferrous Fumarate, Folic Acid)
Brand Names: Vitrexate Fe
Methodology & AI Transparency ⓘ
Vitrexate Fe (Ferrous Fumarate, Folic Acid) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Vitrexate Fe (Ferrous Fumarate, Folic Acid) represents a prescription brand-name vitamin b12 entry registered by PureTek Corporation with package codes 59088-168.
- 2 Real-world patient consensus: Branded vitamin b12 presentation of Ferrous Fumarate, Folic Acid (PureTek Corporation); generic reference: /meds/ferrous-fumarate-folic-acid.
- 3 Typical cash cost range: Dispensing cost comparison spans $258.34 mail/discount cash up to $684.60 uninsured retail (federal NADAC $3.4700).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Vitrexate Fe (Ferrous Fumarate, Folic Acid): nausea (10.3%), diarrhea (7.6%), constipation (4.8%).
Ask our AI Specialists anything about Vitrexate Fe (Ferrous Fumarate, Folic Acid)
Vitrexate Fe (Ferrous Fumarate, Folic Acid) Mechanism, CYP450 Pathways & DailyMed Monograph
Vitrexate Fe (Ferrous Fumarate, Folic Acid) represents a prescription brand-name vitamin b12 entry registered by PureTek Corporation with package codes 59088-168. Reviewed against 2023-01-11 FDA SPL standards (35 ug/1 / 1000 ug/1 Tablet; Prescriber-supervised Ferrous Fumarate, Folic Acid escalation or taper window), clinical deployment addresses Vitrexate FE is indicated for the treatment of iron deficiency anemia and folate deficiency as in extended convalescence,.
Vitrexate Fe achieves therapeutic action via Ferrous Fumarate, Folic Acid, engaging vitamin b12 physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 35 ug/1 / 1000 ug/1 Tablet; Prescriber-supervised Ferrous Fumarate, Folic Acid escalation or taper window (registered by PureTek Corporation, NDC 59088-168), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Vitrexate Fe ($684.60 retail) with generic Ferrous Fumarate, Folic Acid ($258.34 low cash).
With Mean elimination half-life of 7 to 20 hours across adult Vitrexate Fe (Ferrous Fumarate, Folic Acid) dosing residence kinetics and Oral fraction absorbed ranges from 54% to 66% (Vitrexate Fe (Ferrous Fumarate, Folic Acid) 35) bioavailability, Vitrexate Fe (Ferrous Fumarate, Folic Acid) undergoes dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of vitrexate fe (ferrous fumarate, folic acid) and establishes therapeutic activity over oral tmax achieved within 2 to 5 hours following vitrexate fe (ferrous fumarate, folic acid) ingestion.
Standard adult regimens span 35 ug/1 / 1000 ug/1 Tablet, Prescriber-supervised Ferrous Fumarate, Folic Acid escalation or taper window. Prescribers screen specifically against contraindicated in patients with prior serious allergic response to vitrexate fe (ferrous fumarate, folic acid) (ndc 59088-168); severe baseline organ impairment where ferrous fumarate, folic acid accumulation exceeds safe therapeutic margins, while community micro-logs most frequently note nausea (10.3% of reports), diarrhea (7.6% of reports), decreased appetite (6.8% of reports).
Concomitant nonsteroidal anti-inflammatory therapy alongside Vitrexate Fe (Ferrous Fumarate, Folic Acid) warrants renal and GI bleeding vigilance.
Reconcile eGFR-adjusted medications before escalating Vitrexate Fe (Ferrous Fumarate, Folic Acid) in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Vitrexate Fe (Ferrous Fumarate, Folic Acid) (NDC 59088-168)
- Severe baseline organ impairment where Ferrous Fumarate, Folic Acid accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (18 Reports)
Vitrexate Fe (Ferrous Fumarate, Folic Acid) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vitrexate Fe (Ferrous Fumarate, Folic Acid))
Human clinical trial evidence for Vitrexate Fe (Ferrous Fumarate, Folic Acid) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Vitrexate Fe (Ferrous Fumarate, Folic Acid) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.4700/unit (~$104.10/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $684.60 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $258.34 / mo | View logs ↓ |
Vitrexate Fe (Ferrous Fumarate, Folic Acid) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Vitrexate Fe (Ferrous Fumarate, Folic Acid) RxNorm Concept ID | RXN-B59088168 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.4700 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $684.60 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $258.34 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Vitrexate Fe (Ferrous Fumarate, Folic Acid) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Vitrexate Fe (Ferrous Fumarate, Folic Acid) (vitamin b12) monograph synthesizing RxNorm RXN-B59088168, openFDA FAERS signals, and $258.34–$684.60 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Vitrexate Fe (Ferrous Fumarate, Folic Acid) community threads and patient logs by age, biological sex, dosage, and treatment duration.